Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GABRA2 | P47869 | 8/20 | 0.41 |
| ▸ | GABRB2 | P47870 | 8/20 | 0.41 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.39 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.39 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13242132 | 0.83 | GAA (0.56) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL3038457 | 0.83 | GAA (0.56) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL18990731 | 0.82 | GAA (0.54) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL13242163 | 0.82 | GAA (0.45) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL21379846 | 0.81 | GAA (0.53) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL13221251 | 0.80 | GAA (0.43) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL23361271 | 0.79 | GAA (0.51) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL25457039 | 0.77 | GAA (0.44) | GAAKDM4EPOLBGABRA2GABRB2 | |
| SCHEMBL13221258 | 0.76 | IGF1R (0.49) | GAA | |
| SCHEMBL26079081 | 0.76 | GAA (0.56) | GAAKDM4EPOLBGABRA2GABRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | Revolution Medicines, Inc. | 2023-05-11 | — | — | US | disclosed |
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | REVOLUTION MEDICINES INC (US) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135584-A1 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | GAA 990/4885KDM4E 4659/4885POLB 3902/4885 |
| US-20230148450-A9 | BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF | SOST, SOS1, SOS2 | GAA 990/4885KDM4E 4659/4885POLB 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.